Among many combinatorial approaches being tested in preclinical settings, a combination of Ruxolitinib with Lysine Specific Demethylase 1 (LSD1) inhibitor recently demonstrated a synergistic survival improvement in mouse models of CEBPA- and CSF3R-mutated AML [97]. The gene discussed is CSF3R; the disease is acute myeloid leukemia.